Advances in hepatitis C virus vaccines, part two: Advances in hepatitis C virus vaccine formulations and modalities

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 4, 2012, Pages 391-415

  Roohvand, Farzin ^a   Kossari, Niloufar ^b  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

adjuvant; chimeric vaccines; HCV DNA vaccine; HCV proteins; HCV vaccines; hepatitis C virus; immunomodulator; recombinant viral vectors

Indexed keywords

DNA VACCINE; HEPATITIS C VACCINE; RECOMBINANT PROTEIN;

CLINICAL TRIAL; DRUG FORMULATION; HEPATITIS C; HUMAN; NONHUMAN; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HEPACIVIRUS; HEPATITIS C; HUMANS; PATENTS AS TOPIC; VACCINES, DNA; VACCINES, SUBUNIT; VIRAL HEPATITIS VACCINES;

EID: 84859646587     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.673589     Document Type: Review

References (191)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus, Clin Microbiol Infect. 2011; 17(2):107-15
2. Hepatitis C. World Health Organization. Fact sheet N0164 June 2011. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/index.html [Accessed January 2012]
3. Smith RE. Hepatitis C virus therapies. Nat Rev Drug Discov 2006;5:715-16 (Pubitemid 44323697)
4. Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. 2011; 8(2):69-71
5. Vezali E, Aghemo A, Colombo M. Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin Biol Ther 2011;11(3):301-13
6. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part one: advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Patents 2011;21(12):1811-30 This article reviews the cutting edge advances of basic knowledge and novel study tools on HCV for targeted design and evaluation of efficient HCV vaccines.
7. Eisenstein M. Vaccines: a moving target. Nature 2011;8:474(7350):S16-17 This article provides a short but elegant summary on several HCV vaccine candidates in the phase I/II of clinical trials.
8. Tokyo Metropolitan Org Med Res and Toray Industries. Nucleic acid construct containing full-length genome of human Hepatitis C virus, recombinant full-length virus genome replicative cell having the nucleic acid construct transferred thereinto and method of constructing hepatitis C viral particles. WO2005080575; 2005 This patent describes the innovative invention of the first efficient HCV (JFH1) culture system for robust production of viral particles.
9. Biomerieux SA, Inst Nat Sante Rech Med. Composition comprising specific non-structural proteins of hepatitis C virus, useful as prophylactic or therapeutic vaccines, also related expression vectors, microorganisms and antibodies. FR2855758; 2004
10. Chiron Corp. Hepatitis C Virus Asialoglycoproteins. WO9533053; 1995
11. Chiron Corp. Novel Hepatitis C E1 and E2 Truncated Polypeptides and Methods of obtaining the same. WO9604301; 1996
12. Schijns V, Brewer MJ. New views on immunopotentiators in modern vaccines. Expert Rev Vaccines 2008;7(7):877-9 This review summarizes novel vaccine adjuvants/carriers for human applications.
13. Naarding MA, Falkowska E, Xiao H, et al. Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice. Vaccine 2011;29(16):2910-17
14. Chiron Corp. Adjuvant formulation comprising a submicron oil droplet emulsion. WO9014837; 1990
15. Amgen, Inc. and Univ Southern California. Recombinant Dna Derived Cholera Toxin Subunit Analogs. WO9219265; 1992
16. Chiron Corp. Microparticles with adsorbent surfaces, methods of making same, and uses thereof. US6884435; 2005
17. Smithkline Beecham Biolog. Hepatitis Vaccines Containing 3-O-Deacylated Monophoshoryl Lipid A. WO9319780; 1993
18. Smithkline Beecham Biolog. Novel (Adjuvant) Compositions (For Vaccines). WO9857659; 1998 and WO200117550; 2001
19. Smithkline Beecham Biolog. Oil in water vaccine compositions. WO9856414; 1998
20. Smithkline Beecham Biolog. Vaccines. WO9517210; 1995
21. Smithkline Beecham Biolog. Vaccines Against Hepatitis C. WO9701640; 1997
22. Smithkline Beecham Biolog. Vaccine Compositions Containing 3-O Deacylated Monophosphoryl Lipid A. WO9421292; 1994
23. Smithkline Beecham Biologicals. Oil in water emulsions containing saponins. WO199911241; 1999
24. Papahadjopoulos DP, Szoka FC. Method of encapsulating biologically active materials in lipid vesicles. US4235871; 1980
25. Liposome Technology, Inc. Liposomes with enhanced circulation time. US4837028; 1989
26. Aventis Pasteur. Use of an amphipathic compound for providing an adjuvant to a subunit vaccine. US6472159; 2002
27. Immunovaccine Technologies, Inc. Vaccines with enhanced immune response and methods for their preparation. US2002110568; 2002
28. Chua BY, Eriksson EM, Brown LE, et al. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008;26(37):4866-75
29. Leroux-Roels G, Batens AH, Desombere I, et al. Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoingchronic HCV infection. Hum Vaccin 2005;1(2):61-5 This article provides results of a phase I study on one of the first subunit vaccines prepared against HCV infection.
30. Wedemeyer H, Mazur W, Nevens F. Factors influencing progression of liver fibrosis in patients with chronic hepatitis C: results of the 3-year T2S-918-HCV study with HCVE1 therapeutic vaccine. J Hepatol 2008;48:S27-8
31. Verstrepen BE, Depla E, Rollier CS, et al. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis 2011;204(8):37-44
32. Chiron Corp. HCV E1E2 vaccine compositions. US2009258033; 2009
33. Chiron Corp. NANBV diagnostics and vaccines. US6346375; 2002
34. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005;436:961-6 (Pubitemid 41191672)
35. ClinicalTrials.gov Identifier: NCT00500747. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00500747 [Accessed on January 2012] This web site provides the results of the phase I studies on HCV MF59 + r*E1/E2 vaccine.
36. Frey SE, Houghton M, Coates S, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010;28(38):6367-73 This article provides results of a phase I study on E1E2+ MF59 subunit vaccine.
37. Morein B. Matrix With Immunomodulating Activity. US5679354; 1997
38. CSL Ltd. Immunogenic complexes and methods relating there to. WO200048630; 2000
39. Takahashi HT, Takeshita B, Morein S, et al. Induction of CD81 cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990;344:873
40. Wilson ADK, Lovgren-Bengtsson M, Villacres-Ericsson B, et al. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into ISCOMs primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Vaccine 1999;17:1282
41. Csl Ltd. Chelating Immunostimulating Complexes. WO9836772; 1998
42. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009;27(33):4388-401 This article provides a detailed description on different aspect of ISCOMs as adjuvants.
43. Csl Ltd. and Chiron Corp. Vaccine Compositions. US2010047271; 2010
44. Pratten MK, Lloyd JB. Pinocytosis and phagocytosis: the effect of size of a particulate substrate on its mode of capture by rat peritoneal macrophages cultured in vitro. Biochim Biophys Acta 1986;881:307
45. Polakos N, Drane D, Cox J, et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 2001;166:3589-98 (Pubitemid 33117365)
46. Drane D, Maraskovsky E, Gibson R, et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine. A phase I study in healthy volunteers. Hum Vaccin 2009;5(3):151-7 This article provides results of a phase I study on core+ISCOMATRIX vaccine subunit vaccine.
47. United States Dept. of Health and Human Services, US. Chitosan enhancement of immune responses. WO2008039390; 2008
48. Aparna Biosciences, USA. Therapeutic and vaccine polyelectrolyte nanoparticle compositions. WO2009079066; 2009
49. Ct De Immunologia Molecular. Pharmaceutical Compositions Enhancing the Immunogenicity of Poorly Immunogenic Antigens. EA2003000064020011206; 2004
50. Roohvand F, Aghasadeghi MR, Sadat SM, et al. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun 2007;354(3):641-9 This article reports the results of a comparative study for HCV core protein immunization in various adjuvant formulations. (Pubitemid 46186232)
51. Jin B, Wang RY, Qiu Q, et al. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology 2007;122(1):15-27 (Pubitemid 47222591)
52. Qiu Q, Wang RY, Jiao X, et al. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine 2008;26(43):5527-34 This article reports the results of studies on combination of CpG and ISA 720 for various HCV proteins.
53. University of California. Immunostimulatory combinations of receptor agonists for vaccines and tumor immunotherapy. WO2007120368; 2007
54. Coley Pharmaceuticals GmbH. Immunostimulatory P-class oligonucleotide formulations for use in treating diseases and as vaccine adjuvants. WO2007095316; 2007
55. Yu H, Babiuk LA, van Drunen Littel-van den Hurk S, et al. Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol 2004;85:1533-43 (Pubitemid 38807750)
56. Changchun Huapu Biotechnology. CPG single-strand deoxynucleotides for use as adjuvant. WO2006056142; 2006
57. Qiao M, Murata K, Retal DA. Hepatitis C virus like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology 2003;37(1):52-9 (Pubitemid 36042144)
58. HS, M, JeongQiaoNascimbeni M, et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004;78(13):6995-7003
59. Elmovalid GA, Qiao M, Jeong SH, et al. Immunization with hepatitis C virus-like particles results in control of HCV infection in chimpanzees. Proc Natl Acad Sci USA 2007;104(20):8427-32 This article reports the results of studies on immunization ofchimpanzees with insect derived-VLPs formulated with modern adjuvants. (Pubitemid 47175504)
60. Vajdy M, Selby M, Medina-Selby A, et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 2006;87:2253-62 (Pubitemid 44178102)
61. Han DK, Park K, Kim J-J. Thermosensitive pluronic Derivative Hydrogels With High Biodegradability And Biocompatibility For Tissue Regeneration and Preparation Method Thereof. US2010098762; 2010
62. Wyeth Corp. Mycoplasma Hyopneumoniae Bacterin Vaccine. US2010062018; 2010
63. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247(4949 Pt 1):1465-8 The first report, indicating that direct injection of plasmid DNA in vivo results to gene expression.
64. Vical, Inc. and Wisconsin Alumni Res Found. Delivery of exogenous DNA sequences in a mammal. US5580859; 1996
65. Vical, Inc. and Wisconsin Alumni Res Found. Induction of a protective immune response in a mammal by injecting a DNA sequence. US5589466; 1996
66. Merck & Co, Inc. and Innogenetics NV. Polynucleotide tuberculosis vaccine. US5736524; 1998
67. Univ California. Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides. US5679647; 1997
68. Davis BS, Chang GJ, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001;75(9):4040-7 This report provided the basis for the first approved DNA vaccine (protection of horses against West Nile Virus infection). (Pubitemid 32410116)
69. Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo Electroporation. US2006084938; 2006 This patent provided the basis for the delivery of DNA vaccines by non-invasive in vivo Electroporation.
70. Univ. Leland Stanford Junior. Intracellular delivery of nucleic acids using pressure. US5922687; 1999
71. Du Pont. Method and Apparatus for Introducing Biological Substances Into Living Cells. US5204253; 1993
72. Capone S, Zampaglione I, Vitelli A, et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 2006;177(10):7462-71 This article provided the clear evidence for enhancement of immune responses by electroporation mediated delivery of antigens. (Pubitemid 44715117)
73. Univ. California. Methods and Compositions for In Vivo Gene Therapy. WO9324640; 1993
74. Univ. Yale. Liposomal transfection of nucleic acids into animal cells. US5279833; 1994
75. Molecular Express, Inc. Immunogenic Liposome compositions. EA004797; 2004
76. Powderject Vaccines, Inc. Adjuvanted genetic vaccines. WO2001032208; 2001
77. US Health. Surface Targeted Expression of A Modified Hepatitis C Virus Envelope Protein. WO9966033; 1999
78. Forns X, Emerson SU, Tobin GJ, et al. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellular and on the cell surface. Vaccine 1999;17(15-16):1992-2002 (Pubitemid 29172370)
79. Univ Wuhan. The DNA vaccine of an anti-infection of hepatitis C virus. CN1943789; 2007
80. Lagging LM, Meyer K, Hoft D, et al. Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 1995;69(9):5859-63 One of the first articles, reporting HCV DNA vaccine immunization.
81. Hartoonian C, Ebtekar M, Soleimanjahi H, et al. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine 2009;46(1):43-50
82. Cigb. Vaccine Composition Potentiated with DNA and Antigen Combination. RU2294212; 2007
83. Alvarez-Lajonchere L, Shoukry NH, Gra B, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepat 2009;16(3):156-67
84. Castellanos M, Cinza Z, Dorta Z, et al. Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. J Gene Med 2010;12(1):107-16
85. Tripep AB. Hepatitis C Virus Codon Optimized Non-Structural NS3/4A Fusion Gene. US2010104592; 2010
86. Ahlen G, Nystrom J, Pult I, et al. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis 2005;192:2112-16 (Pubitemid 41779209)
87. Ahlen G, Soderholm J, Tjelle T, et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression inflammation, and infiltration of CD3+ T cells. J Immunol 2007;179:4741-53
88. ClinicalTrials.gov Identifier: NCT00563173. Available from. http://clinicaltrials.gov/show/NCT00563173 [Accessed on January 2012] This web site provides the results of the phase I studies on ChronVac-C vaccine.
89. Kast WM, Melief CJ. In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes. Immunol Lett 1991;30:229-32 This review summarizes the different aspects of epitopic/peptide (CTLs) immunization.
90. Buteau C, Markovic SN, Celis E. Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc 2002;77:339--349.
91. Toussaint NC, Maman Y, Kohlbacher O, et al. Universal peptide vaccines - optimal peptide vaccine designbased on viral sequence conservation. Vaccine 2011;29(47):8745-53
92. Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50(3-4):213-19 (Pubitemid 30099526)
93. Merck & Co, Inc. System and method for automated selection of T-cell epitopes. WO2006124408; 2006
94. Epimmune, Inc. HLA binding motifs and immunogenic peptides and their uses for vaccines against desired antigens. US20070055049; 2007 This patent introduces the software and databases for identification of CTL and epitopic peptides.
95. Henry M. Jackson Foundation for the Advancement of Military Medicine Institute. Targeted identification of immunogenic peptides. WO2009112792; 2009
96. Epimmune, Inc. Hla Binding Peptides and Their Uses. WO0220035; 2002
97. Algonomics NV. Method, Computing Routine, Device for Predicting Properties of MHC/PEPTIDE Complexes, and Data and Peptides Produced Therefrom. WO03105058; 2003
98. Imp College Innovations Ltd. Identification of HLA-DR Restricted HCV Epitopes. WO0234770; 2002
99. Epimmune, Inc. Inducing cellular immune responses to Hepatitis C virus using peptide and nucleic acid compositions. WO0121189; 2001
100. Scripps Research Inst. Peptides for Inducing Cytotoxic T Lymphocyte Responses to Hepatitis C Virus. WO9525122; 1995
101. Innogenetics NV. Immunodominant Human T-Cell Epitopes of Hepatitis C Virus. WO9512677; 1995 and JP2004194668; 2004
102. Cytel Corp. HLA-A2.1 and HLA Binding Peptides and Their Uses. WO9420127; 1994 and WO9403205; 1994
103. Pharmexa, Inc. Inducing Cellular Immune Responses to Hepatitis B Virus Using Peptide and Nucleic Acid Compositions. US2010068228; 2010
104. Epimmune, Inc. Compositions and methods for eliciting CTL immunity. US6419931; 2002
105. Cytel Corp. Alteration of immune response using pan DR-binding peptides. US5736142; 1998
106. Immuosystems Gmbh. Epitopes of Virus Hepatitis C Specifically CD4+ T Lymphocytes. WO0226785; 2002
107. Innogenetics N.V. and IDM Pharma, Inc. Peptides for inducing a CTL and/or HTL responses to Hepatitis C virus. WO2005118626A2; 2005
108. US Health. Hepatitis C Virus Core Peptide for Stimulation of Cytotoxic T Lymphocytes and Diagnosis of HCV Exposure. WO9527733; 1995
109. Wedemeyer H, Berg T, Manns MP, et al. Induction of the TH1/TC1 type immunity in chronic hepatitis C non-responder patients with the therapeutic peptide vaccine IC41. J Hepatol 2005;42(Suppl 2):A19
110. Frisch J, Tauber E, Buerger V, et al. HCV Vaccines for Chronic HCV Patients. US2010322972; 2010
111. Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006;24:4343-53 This article provides the results of the phase I studies on IC41 vaccine.
112. Klade CS, Wedemeyer H, Berg T, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroent 2008;134:1385-95
113. Buschle M, Frisch J, Klade C, et al. HCV vaccines. US2009130135; 2009
114. Wedemeyer H, Schuller E, Schlaphoff V, et al. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 2009;27(37):5142-515
115. Firbas C, Boehm T, Buerger V, et al. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine 2010; 28(12):2397-407 This article provides the results of the phase II studies on IC41 vaccine.
116. Yutani S, Yamada A, Yoshida K, et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 2007;25(42):7429-35 (Pubitemid 47484009)
117. Green Peptide Co. Ltd. Peptide Derived from Hepatitis C Virus. US2010292138; 2010
118. Yutani S, Komatsu N, Shichijo S, et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci 2009;100(10):1935-42
119. Fytili P, Dalekos GN, Schlaphoff V, et al. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine 2008;26:3818-26
120. Intercell AG. Method for Isolating Hepatitis C Virus Peptide. US2009081246; 2009 and JP2010265262; 2010
121. Gowans EJ, Roberts S, Jones K, et al. A Phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010;53(4):599-607
122. Moser C, Amacker M, Kammer AR, et al. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccin 2007;6(5):711-21 (Pubitemid 47610491)
123. Pevion Biotech AG. Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof. EP2014279; 2009
124. ClinicalTrials.gov Identifier: NCT00445419. Available from: http://clinicaltrials.gov/show/NCT00445419 [Accessed on January 2012] This web site provides the results of the phase I studies on PEVION BIOTECH AG. HCV virosome vaccine.
125. Memarnejadian A, Roohvand F, Arashkia A, et al. Polytope DNA vaccine development against hepatitis C virus:a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett 2009; 16(7):842-50 This article provides a practical and step by step approach for design, construction and evaluation of the immune responses to HCV polytope vaccines.
126. Arashkia A, Roohvand F, Memarnejadian A, et al. Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice. Virus Genes 2010;40(1):44-52 This article reports the enhancing effect of PADRE and ERss on immune responses to HCV polytope vaccine.
127. Im EJ, Hong JP, Roshorm Y, et al. Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog 2011;7(5):e1002041 This article reports the importance of subdominant HCV epitopes for construction of HCV polytope vaccines.
128. Zhang Y, Ma CJ, Ni L, et al. Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection. J Immunol 2011;186(5):3093-103
129. Memarnejadian A, Roohvand F. Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine. Cell Immunol 2010;261(2):93-8 This article reports the importance of both prime/boosting and HBsAg fusion (particulate formation) in enhancing the immune responses to HCV polytopes.
130. Martin P, Simon B, Lone YC, et al. A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine 2008; 26(20):2471-81
131. Chiron Corp. Multiple Epitope Fusion Protein. WO9744469; 1997
132. Chiron Corp. Hepatitis C virus multi copy epitope fusion antigens. US6428792; 2002
133. First Hospital of Jilin Univer. Multi-epitope gene of hepatitis C and its nucleic acid vaccine. CN1690207; 2005
134. Nationwide Childrens Hospital. AVV Vectors and Methods. US2010260800; 2010
135. Univ Massachusetts. Novel AAV 'S and Uses Thereof. WO2010138263; 2010
136. Targeted Genetics Corp. and Childrens Hospital, Inc. Recombinant AAV Based Vaccine Methods. WO2006073496; 2006
137. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5 (Pubitemid 34087555)
138. Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:6305-13 (Pubitemid 36588400)
139. D'Ambrosio E, Del Grosso N, Chicca A, et al. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J Hyg 1982;89:155-61 (Pubitemid 12051350)
140. Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA, Italy. Chimpanzee adenovirus vaccine carriers. WO2005071093; 2005
141. The Trustees of the University of Pennsylvania, USA. Sequences for simian adenoviruses of subfamily C, SAdV-40, SAdV-31 or SAdV-34, and uses thereof for gene delivery, vaccination and recombinant production. WO2009105084; 2009
142. Kaslow David C, Bett Andrew J. Hepatitis C virus Vaccine. US2010129901; 2010
143. Capone S, Meola A, Ercole BB, et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that Overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006;80(4):1688-99 This article introduces the employment of Ad6 vector for immunization aims.
144. Fattori E, Zampaglione I, Arcuri M, et al. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther 2006;13:1088-96
145. Okairos. AG Switzerland. Simian Adenovirus Nucleic Acid- and Amino Acid-Sequences, Vectors Containing same, and Uses Thereof. WO2010086189; 2010
146. Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006;12:190-7 (Pubitemid 43214745)
147. Colloca S, Folgori A, Lahm A. Hepatitis C Virus Nucleic Acid Vaccine. US2009035277; 2009
148. ClinicalTrials.gov Identifier: NCT01070407. Available from: http://clinicaltrials.gov/ct2/show/NCT01070407 [Accessed on January 2012] This web site provides the results of the phase I studies on Okairos HCV virosome vaccine.
149. Mikkelsen M, Holst PJ, Bukh J, et al. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J Immunol 2011;186(4):2355-64
150. Peking University Peoples Hospital. Anti-HCV Vaccine and Preparation Methods and Uses Thereof. US2010310605; 2010
151. Li W, Krishnadas DK, Li J, et al. Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy. J Immunol 2006;176(10):6065-75
152. Mayr A, Stickl H, Muller HK, et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl Bakteriol 1978;167(5--6):375-90
153. Sutter G, Moss B. Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89(22):10847-51
154. Diamond Don and Wang Zhongde. Genetically Stable Recombinant Modified Vaccinia Ankara (RMVA)Vaccines and Methods of Preparation Thereof. US2010316667; 2010
155. Internat Aids Vaccine Initiati. Recombinant Modified Ankara Viral HIV-I Vaccine. WO2008118936; 2008
156. Delcayre A, Laus R, Mandl S. Methods for treating cancer with MVA. US2011008294; 2011
157. Sutter G, Bujard H, Westerfeld N, et al. Recombinan MVA strains as potential vaccines against p. falciparum Malaria. US2006127413; 2006
158. Chaplin P. Recombinant Modified Vaccinia Virus Measles Vaccine. US2011052627; 2011
159. Abraham JD, Himoudi N, Kien F, et al. Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 2004;22(29--30):3917-28
160. Rollier CS, Paranhos-Baccala G, Verschoor EJ, et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007;45:602-13 (Pubitemid 46450611)
161. Transgene SA. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use. US2007269460; 2007
162. Fournillier A, Gerossier E, Evlashev A, et al. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 2007;25:7339-53 (Pubitemid 47484019)
163. ClinicalTrials.gov Identifier: NCT00529321. Available from: http://clinicaltrials.gov/ct2/show/NCT00529321 [Accessed on January 2012] This web site provides the results of the phase I studies on TG4040 HCV vaccine.
164. Li G. Recombinant Alphavirus vectors and methods of using same. US2008096274; 2008
165. Chul Joong K. Preparation of Infectious HCV-Like Particles. KR20030013585. 2003
166. Lin Y, Kwon T, Polo J, et al. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008;82(15):7492-503 (Pubitemid 352031217)
167. Zubkova I, Choi YH, Chang E, et al. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine 2009;27(19):2594-602
168. Stubbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001;7(5):625-9 (Pubitemid 32448332)
169. GlobeImmune, Inc. Yeast-based vaccine for inducing an immune response. WO2007092792; 2007
170. GlobeImmune, Inc. Yeast-Based Therapeutic for Chronic Hepatitis C Infection. US2010150963; 2010
171. Haller AA, Lauer GM, King TH, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 2007;25:1452-63 (Pubitemid 46074294)
172. ClinicalTrials.gov Identifier: NCT00124215. Available from: http://clinicaltrials.gov/ct2/show/ NCT00124215 and yeast pages of globeimmune: http://www.homeyeastinfectionremedy.org/yeast-infection-treatment/ globeimmuneexpands- gi-5005-02-phase-2b-trial-to-include-additional-treatment- naive-il28btt-subjects-with-chronic-genotype-1-hcv/ [Accessed on January 2012]
173. Mishra N, Goyal AK, Tiwari S, et al. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Patents 2010;20(5):661-79
174. Powderject Vaccines, Inc. Powder compositions. WO2001093829; 2001
175. Tripep AB. Transdermal Formulations Containing Hepatitis C Virus Immunogens. WO2008004992; 2008
176. Wedemeyer H, Gagneten S, Davis A, et al. Oral immunization with HCV-NS3-transformed salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 2001; 121(5):1158-66 (Pubitemid 33022096)
177. Cao J, Chen Z, Ren Y, et al. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice. Vaccine 2011;29(20):3714-23
178. Peters J, Stoger E. Transgenic crops for the production of recombinant vaccines and anti-microbial antibodies. Hum Vaccin 2011;7(3):367-74
179. Nemchinov LG, Liang TJ, Rifaat MM, et al. Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Arch Virol 2000;145(12):2557-73 (Pubitemid 32062441)
180. Nuzzaci M, Vitti A, Condelli V, et al. In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine. J Virol Methods 2010; 165(2):211-15
181. Qingdao Science Technology Uni. HCV composite multi-epitope transgene plan oral vaccine. CN101070544; 2007
182. Keating GM, Noble S. Recombinant hepatitis B (Engerix-B) vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003;63:1021-51 (Pubitemid 36575466)
183. Patient R, Hourioux C, Vaudin P, et al. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. New Biotechnol 2009;25(4):226-34
184. Chiron Corp. HBV/HCV virus-like particle. US6740323; 2004.and EP1535628; 2005
185. Univ Wuhan (CN). Yeast strain for preparing PreS-E1-E2 vaccine of hepatitis B and hepatitis C virus and preparation method thereof. CN1908157; 2007
186. Univ Francois Rabelais de Tour (FR). Novel fusion proteins and use thereof for preparing Hepatitis C Vaccines. WO2009153518; 2009
187. Wu CL, Leu TS, Chang TT, et al. Hepatitis C virus core protein fused to hepatitis B virus core antigen forserological diagnosis of both hepatitis C and hepatitis B infections by ELISA. J Med Virol 1999;57:104-10
188. Claeys H, Volckaerts A, Mertens W, et al. Localization and reactivity of an immunodominant domain in the NS3 region of hepatitis C virus. J Med Virol 1995;45:273-81
189. Mihailova M, Boos M, Petrovskis I, et al. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus. Vaccine 2006;24:4369-77
190. Univ First Hospital Jilin. Chimeric antigen gene of hepatitis B and hepatitis C and its nucleic acid vaccine. CN1690206; 2005
191. Tripep AB. Immunogen Platform. US2009214593; 2009